Which is the ideal JAK inhibitor for alopecia areata – Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway
Alopecia areata (AA) is an immune-mediated condition, clinically manifesting as non-cicatricial patches of alopecia. It is often a self-limiting condition; however, regrowth of hair can take a long period of time, resulting in significant psychological comorbidity. With the recent advances in pathom...
Main Authors: | Kabir Sardana, Savitha Bathula, Ananta Khurana |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2023-01-01
|
Series: | Indian Dermatology Online Journal |
Subjects: | |
Online Access: | http://www.idoj.in/article.asp?issn=2229-5178;year=2023;volume=14;issue=4;spage=465;epage=474;aulast=Sardana |
Similar Items
-
Discovery of a novel and highly selective JAK3 inhibitor as a potent hair growth promoter
by: Md Mehedi Hossain, et al.
Published: (2024-04-01) -
Efficacy and safety of different JAK inhibitors in the treatment of alopecia areata: a network meta-analysis
by: Dongfan Wei, et al.
Published: (2023-04-01) -
The efficacy and safety of JAK inhibitors for alopecia areata: A systematic review and meta-analysis of prospective studies
by: Diqin Yan, et al.
Published: (2022-08-01) -
Efficacy and safety of baricitinib in patients with alopecia areata: evidence to date
by: Sofia Faria, et al.
Published: (2023-09-01) -
Therapeutic Maintenance of Baricitinib and Tofacitinib in Real Life
by: Valentine Deprez, et al.
Published: (2020-10-01)